tbuckley/cabot-search huggingface dataset:
Pegylated liposomal doxorubicin (Peg-LD) and paclitaxel in patients with metastatic breast carcinoma: A phase II study
Authors: B. Winograd, V. Leonardi, V. Palmisano, A. Pepe, G. Savio, A. Laudani, L. Blasi, M. Alù, G. Rondello, M. P. Cusimano, B. Agostara
Journal: Journal of Clinical Oncology (2005)

884 Introduction: Systemic chemotherapy has saved the life of many patients with cancer, but the maximum efficacy of cytotoxic agents is severely limited by their adverse effects. Peg-LD has the advantage of delivering the active anthracycline directly to the tumor site while exposing the patient to a lesser degree of doxorubicin-associated toxicities. More recently, a regimen in which Paclitaxel is infused weekly over 1 hour produced substantial anti-tumor activity, with little myelosuppression. Materials and Methods: We designed a phase II trial to study the efficacy and toxicity of Paclitaxel 70 mg/m2 weekly in metastatic breast cancer patients with high cardiologic risk. All patients were premedicated with Pyridoxine 300 mg/daily per os and Desametasone 8 mg i.v. before each chemotherapy administration to prevent the palmar-plantar erythrodysesthesia (PPE). To date, 15 pts have been recruited, 12 pts (80%) evaluable for efficacy and 15 pts (100%) for toxicity. Adjuvant chemotherapy had been administered in 12 pts (anthracycline-based in 7 pts); 12 pts (80%) have two or more sites of disease. Efficacy: Overall, 1 CR, 7 PR and 3 NC have been recorded with an overall response rate of 66%. 3 NC and 1 PD had been registered. Toxicity: Toxicity was generally manageable; the only grade 3,4 side effects recorded were: PPE 13%, mucositis 6%, Leucopenia 20%, AST/ALT 6%. No cardiotoxicity, no neurotoxicity, no alopecia was seen. Conclusions: The weekly Paclitaxel and Peg-LD appears to be a well tolerated and effective approach in advanced breast cancer patients with high cardiologic risk. This phase II study will continue to accrue patients until 40 pts are enrolled. No significant financial relationships to disclose.
Discrimination of Long and Short Survival in Follicular Lymphoma (FL) Patients by Incidence of FOXP3 and Perifollicular Incidence of CD4 and CD7 Using Immunohistochemistry on Tissue Microarray (TMA) of Diagnostic Lymph Nodes (LN).
Authors: Lindsey K. Goff, Abigail M. Lee, Andrew Clear, Maria Calaminici, Andrew J. Davies, Suzanne Jordan, Finlay Macdougall, Janet Matthews, Andrew J. Norton, John G. Gribben, Thomas A. Lister
Journal: Blood (2005)
Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients
Authors: Deborah M Stephens, Amy S. Ruppert, Kristie A. Blum, Jeffrey A. Jones, Joseph M. Flynn, Amy J. Johnson, Jia Ji, Mitchell Phelps, Michael R. Grever, John C. Byrd
Journal: Blood (2010)
Early death after discharge from emergency departments: analysis of national US insurance claims data
Authors: Ziad Obermeyer, Brent Cohn, Michael Wilson, Anupam B Jena, David M Cutler
Journal: BMJ (2017)

To measure incidence of early death after discharge from emergency departments, and explore potential sources of variation in risk by measurable aspects of hospitals and patients. Retrospective cohort study. Claims data from the US Medicare program, covering visits to an emergency department, 2007-12. Nationally representative 20% sample of Medicare fee for service beneficiaries. As the focus was on generally healthy people living in the community, patients in nursing facilities, aged ≥90, receiving palliative or hospice care, or with a diagnosis of a life limiting illnesses, either during emergency department visits (for example, myocardial infarction) or in the year before (for example, malignancy) were excluded. Death within seven days after discharge from the emergency department, excluding patients transferred or admitted as inpatients. Among discharged patients, 0.12% (12 375/10 093 678, in the 20% sample over 2007-12) died within seven days, or 10 093 per year nationally. Mean age at death was 69. Leading causes of death on death certificates were atherosclerotic heart disease (13.6%), myocardial infarction (10.3%), and chronic obstructive pulmonary disease (9.6%). Some 2.3% died of narcotic overdose, largely after visits for musculoskeletal problems. Hospitals in the lowest fifth of rates of inpatient admission from the emergency department had the highest rates of early death (0.27%)-3.4 times higher than hospitals in the highest fifth (0.08%)-despite the fact that hospitals with low admission rates served healthier populations, as measured by overall seven day mortality among all comers to the emergency department. Small increases in admission rate were linked to large decreases in risk. In multivariate analysis, emergency departments that saw higher volumes of patients (odds ratio 0.84, 95% confidence interval 0.81 to 0.86) and those with higher charges for visits (0.75, 0.74 to 0.77) had significantly fewer deaths. Certain diagnoses were more common among early deaths compared with other emergency department visits: altered mental status (risk ratio 4.4, 95% confidence interval 3.8 to 5.1), dyspnea (3.1, 2.9 to 3.4), and malaise/fatigue (3.0, 2.9 to 3.7). Every year, a substantial number of Medicare beneficiaries die soon after discharge from emergency departments, despite no diagnosis of a life limiting illnesses recorded in their claims. Further research is needed to explore whether these deaths were preventable.
CONCUSSIONS IN INTERNATIONAL ICE HOCKEY CHAMPIONSHIPS AND OLYMPIC WINTER GAMES BETWEEN 2006 AND 2015
Authors: Markku Tuominen, Timo Hänninen, Jari Parkkari, Michael J. Stuart, Teemu M. Luoto, Pekka Kannus, Mark Aubry
Journal: British Journal of Sports Medicine (2017)

Objective To describe the occurrence and trend of concussions during the international ice hockey tournaments. Design Register study. Setting The International Ice Hockey Federation (IIHF) World Championships and Olympic Winter Games. Participants A total of 3293 games were played in the 169 tournaments by 1212 teams (26130 players) comprising 142244 athletic game exposures. Outcome measures One hundred and sixty concussions were observed. Main Results The average injury rate (IR) for concussion was 1.1 per 1000 ice hockey player-games for all IIHF World Championship tournaments (WC). The injury rate was highest in men's WC A-pool tournaments and Olympic Winter Games (OWG) (IR 1.6), and lowest in women's WC and OWG (IR 0.9). However, the annual injury rate for concussion in men's tournament has been lower than that in World Junior tournaments since 2012. When concussion occurred in a contact with a flexible board injury rate was 0.2 per 1,000 player games and 1.1 if a board and glass were traditional [RR 6.4, (95% CI 1.50–27.61]. In men's tournaments the trend of concussions caused by illegal hits decreased over a study period. After the 2012 Zurich Consensus Guidelines none of the concussed players returned to a play during a same day in men's WC tournaments. Conclusions The risk of concussion was significantly lower if games were played on rinks with flexible board and glass. Between 2006 and 2015, the annual risk of concussion in men's WC has been decreasing most likely due to the decreasing number of concussions caused by illegal hits.
A Comparative Analysis of the Leukaemic Potential of Mature T Cells Versus T Cell Precursors.
Authors: Sebastian Newrzela, Christopher Baum, Zhixiong Li, Martin-Leo Hansmann, Sylvia Hartmann, Marianne Hartmann, Kerstin Cornils, Boris Fehse, Dorothee M. von Laer
Journal: Blood (2006)
Quantitative Analysis of Small Molecular Weight Thiols and Disulfides in Blood from a Sickle Cell Disease Patient Infused with N-Acetyl-L-Cysteine
Authors: Shelby A Cate, Tahsin Ozpolat, Junmei Chen, Colette Norby, Barbara A. Konkle, Jose A. Lopez, Xiaoyun Fu
Journal: Blood (2014)
Homozygosity for Killer Immunoglobin-like Receptor (KIR) Haplotype a Is Associated to Negative Interim Positron Emission Tomography (PET) and a Favourable Outcome in Hodgkin Lymphoma
Authors: Giovanni Caocci, Roberto Littera, Sara Oppi, Marianna Greco, Ivana Celeghini, Rossella Caria, Sara Lai, Nicola Orrù, Massimo Martino, Carlo Carcassi, Andrea Gallamini, Giorgio La Nasa
Journal: Blood (2014)
Chemical Treatment of Tumors. VIII. Ultracentrifugal and Electrophoretic Analysis of the Hemorrhage-Producing Fraction from &lt;italic&gt;Serratia marcescens (Bacillus prodigiosus)&lt;/italic&gt; Culture Filtrate
Authors: Herbert Kahler, M. J. Shear, J. L. Hartwell
Journal: JNCI Journal of the National Cancer Institute (1943)

Chemical Treatment of Tumors. VIII. Ultracentrifugal and Electrophoretic Analysis of the Hemorrhage-Producing Fraction from Serratia marcescens (Bacillus prodigiosus) Culture Filtrate Herbert Kahler, Herbert Kahler senior biophysicist Search for other works by this author on: Oxford Academic PubMed Google Scholar M. J. Shear, M. J. Shear principal biochemist Search for other works by this author on: Oxford Academic PubMed Google Scholar J. L. Hartwell J. L. Hartwell chemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 4, Issue 1, August 1943, Pages 123–129, https://doi.org/10.1093/jnci/4.1.123 Published: 01 August 1943
Pre-Donor Evaluation of an HLA Matched Sibling Identifies a Novel Inherited RUNX1 Mutation Encoding a Missense Mutation Found Outside of the RUNT Domain in Familial Platelet Disorder
Authors: Jacqueline S Garcia, Jozef Madzo, Devin Cooper, Sarah A Jackson, Kenan Onel, Richard A. Larson, Andrew Artz, Lucy A Godley
Journal: Blood (2010)
Temozolomide in the Era of Precision Medicine
Authors: Anish Thomas, Mamoru Tanaka, Jane Trepel, William C. Reinhold, Vinodh N. Rajapakse, Yves Pommier
Journal: Cancer Research (2017)

In the January 1, 2017, issue of Cancer Research, Nagel and colleagues demonstrate the value of assays that determine the DNA repair capacity of cancers in predicting response to temozolomide. Using a fluorescence-based multiplex flow cytometric host cell reactivation assay that provides simultaneous readout of DNA repair capacity across multiple pathways, they show that the multivariate drug response models derived from cell line data were applicable to patient-derived xenograft models of glioblastoma. In this commentary, we first outline the mechanism of activity and current clinical application of temozolomide, which, until now, has been largely limited to glioblastoma. Given the challenges of clinical application of functional assays, we argue that functional readouts be approximated by genomic signatures. In this context, a combination of MGMT activity and mismatch repair (MMR) status of the tumor are important parameters that determine sensitivity to temozolomide. More reliable methods are needed to determine MGMT activity as DNA methylation, the current standard, does not accurately reflect the expression of MGMT. Also, genomics for MMR are warranted. Furthermore, based on patterns of MGMT expression across different solid tumors, we make a case for revisiting temozolomide use in a broader spectrum of cancers based on our current understanding of its molecular basis of activity. Cancer Res; 77(4); 823-6. ©2017 AACR.
Utility of Combined DNA and RNA Next Generation Sequencing in Leukemias for Identification of Prognostic and Therapeutically Relevant Genomic Alterations in Clinical Practice
Authors: Catherine C. Coombs, Aaron D. Viny, Jie He, Rachel Kobos, Doron Lipson, Neerav Shukla, Kristina M. Knapp, Geoff Otto, Omar Abdel-Wahab, Eytan M. Stein, Raajit K. Rampal, Vincent A. Miller, Ahmet Dogan, Marcel R.M. van den Brink, Scott A. Armstrong, Phil J Stephens, Martin S. Tallman, Ross L. Levine
Journal: Blood (2014)
Genome-wide interaction study of dust mite allergen on lung function in children with asthma
Authors: Erick Forno, Joanne Sordillo, John Brehm, Wei Chen, Takis Benos, Qi Yan, Lydiana Avila, Manuel Soto-Quirós, Michelle M. Cloutier, Angel Colón-Semidey, Maria Alvarez, Edna Acosta-Pérez, Scott T. Weiss, Augusto A. Litonjua, Glorisa Canino, Juan C. Celedón
Journal: Journal of Allergy and Clinical Immunology (2017)
Dying at home depends on wealth, location, and comorbidities, study finds
Authors: Jacqui Wise
Journal: BMJ (2017)

The End of Life Care Strategy has helped to shift some deaths out of hospital among people in England with respiratory disease, research in the open access journal BMC Medicine has shown. However, it found that patients who had multiple diseases or lived in a deprived area were more likely to die in hospital than those who did not.1

Most people prefer to die at home rather than in hospital. In 2004 the National Institute for Health and Care Excellence published …
Breast cancer patients have better outcomes than prostate cancer patients for palliation of painful bone metastases: Results of RTOG 97–14
Authors: W. F. Hartsell, K. Winter, D. W. Bruner, C. W. Scarantino, R. Ivker, M. Roach, J. H. Suh, W. Demas, B. Movsas, I. Petersen, A. Konski
Journal: Journal of Clinical Oncology (2005)

6073 Background: It is unclear whether there are gender-based differences in pain response and survival after palliative external beam radiotherapy (XRT) for painful bone metastases from breast or prostate cancers. Methods: RTOG and NCCTG conducted a randomized, prospective phase III study of XRT for patients with breast or prostate cancer and painful bone metastases (Brief Pain Index (BPI) worst pain score of ≥5 out of 10). Patients were randomized to 8 Gy in a single fraction vs. 30 Gy in 10 fractions, stratified by number of painful sites, weight bearing site, worst pain score and bisphosphonate usage. Results of the primary study are reported elsewhere; XRT was very effective, providing pain relief in 66% of patients. At 3 months follow-up, there was no difference between the two treatment arms, regardless of stratification. Results: In this gender-based analysis, there were 453 women with breast cancer and 445 men with prostate cancer; median age was 58 and 71 years, respectively. Stratification variables were balanced other than more women received bisphosphonates (46% vs 8% of men). Pain relief was evaluated at 3 months using the BPI. For breast and prostate cancer, complete response was seen in 17% and 16% and partial response in 54% and 43% for an overall response rate of 71% and 59% (p=0.0034) Median survival on the 30 Gy arm for women was 11.6 months compared to 7.3 months for men and median survival on the 8 Gy arm for women was 12.5 months compared to 7.9 months for men. Separate multivariate analyses of the 30 Gy arm and 8 Gy arm, showed that women with breast cancer had statistically significantly longer survival compared to men with prostate cancer (30Gy: HR 1.78, p-value <0.0001; 8Gy: HR 1.75, p-value < 0.0001), after adjusting for age (which was not significant) and KPS. Conclusions: Women with bone metastases from breast cancer experience better outcomes in terms of pain control and survival compared to men with prostate cancer with bone mets treated with palliative radiotherapy. Further consideration should be given to tailoring treatment by gender. Acknowledgment: This trial was supported by NCI grants RTOG U10 CA21661, CCOP U10 CA37422, and Stat U10 CA32115. No significant financial relationships to disclose.
QOL-11CHILDREN DRAW OUT EFFECTS OF LIVING WITH A BRAIN TUMOR IN THE FAMILY AND WHAT WORKS
Authors: Petra Hoogendoorn
Journal: Neuro-Oncology (2015)

BACKGROUND: Dutch research shows that 1 out of 3 children with a parent diagnosed with cancer suffers increased posttraumatic stress symptoms for up to several years, for which they should receive psychosocial help. In comparison to other cancer patients, brain tumor patients have tumor location specific neurological impairments that can greatly affect both daily functioning and quality of life. Their caregivers report continuous and extremely high rates of stress (72-86%) and physically and emotionally exhausting time demands. In a study on caregiving at the Neuro Oncology Center at the University of Virginia Health System, five caregivers were wives juggling the demanding care for their afflicted husbands and children living at home. They reported feeling that they were neglecting their children. Unfortunately to date there is no research on what effects living in these conditions has on children and what works for children and their parents. METHOD: In a collaboration of American, British and Dutch patient advocates 20 children confronted with a brain tumor in their family are asked to share - partly through drawings - effects on their daily life. What is difficult, what could help, what works, what is important to them? Their parents complete a questionnaire, which includes a brief overview of symptoms and treatment history, as well as their answers to the same questions as far as parenting is concerned. The children vary in age, time since diagnosis or death, and family situation. RESULTS: Drawings, answers and comments by experts in child psychology and clinical child and adolescence studies will be presented. CONCLUSION: These drawings will serve as the first step to create increased awareness about the effects of a brain tumor on children in the home, which will in turn serve as a basis for additional research, development of resources and best practice standards.
Long-Term Treatment of Alcoholic Liver Disease with Propylthiouracil
Authors: H Orrego, J E Blake, L M Blendis, K V Compton, Y Israel
Journal: New England Journal of Medicine (1987)

Propylthiouracil has been shown experimentally to protect against alcohol-induced hepatocellular necrosis in hypoxic conditions. An earlier, short-term study of patients with alcoholism and liver disease indicated clinical improvement with propylthiouracil, but the effect on mortality could not be assessed. In the present study, we investigated the effect of propylthiouracil on mortality in patients with alcoholic liver disease in a long-term, double-blind, randomized clinical trial involving 310 compliant patients who received propylthiouracil (n = 157) or placebo (n = 153) for a maximum of two years. There were no differences between the two groups in demographic and clinical characteristics and biopsy-confirmed diagnoses at randomization, or in daily urinary alcohol levels during the study. The cumulative dropout rate over two years was not significantly different (propylthiouracil group, 0.68; placebo group, 0.60). The group receiving propylthiouracil (300 mg per day) had a cumulative mortality rate half that in the group receiving placebo (0.13 vs. 0.25 [P less than 0.05] in the total sample, and 0.25 vs. 0.55 [P less than 0.03] in a subgroup of severely ill patients [propylthiouracil group, n = 56; placebo group, n = 41]). Proportional-hazards stepwise regression analyses indicated that only propylthiouracil treatment, prothrombin time, hemoglobin levels, and mean daily urinary alcohol levels significantly affected mortality. The hazards ratio for the complete group indicated that mortality in the propylthiouracil group was 0.38 (95 percent confidence interval, 0.20 to 0.83) that of the placebo group. Protection by propylthiouracil was not observed in patients with high morning urinary alcohol levels. No clinically important side effects of propylthiouracil were observed at the dose used. We conclude that the administration of propylthiouracil can reduce mortality due to alcoholic liver disease.
Treatment Outcome of Aggressive Lymphoma with CyclOBEAP (CHOP-Like + Etoposide and Bleomycin): Results of Multicenter Trial.
Authors: Masataka Okamoto, Nozomi Niitsu, Sadao Aoki, Yasunobu Kuraishi, Hirokazu Okumura, Masami Hirano
Journal: Blood (2004)
Hallucinations and mental imagery demonstrate top-down effects on visual perception
Authors: Piers D. L. Howe, Olivia L. Carter
Journal: Behavioral and Brain Sciences (2016)

In this commentary, we present two examples where perception is not only influenced by, but also in fact driven by, top-down effects: hallucinations and mental imagery. Crucially, both examples avoid all six of the potential confounds that Firestone & Scholl (F&S) raised as arguments against previous studies claiming to demonstrate the influence of top-down effects on perception.
Redox‐Activatable ATP‐Depleting Micelles with Dual Modulation Characteristics for Multidrug‐Resistant Cancer Therapy
Authors: Hebin Wang, Yang Li, Miaozun Zhang, Di Wu, Youqing Shen, Guping Tang, Yuan Ping
Journal: Advanced Healthcare Materials (2017)

A fast adenosine triphosphate (ATP)‐depleting micellar system that is activated by intracellular redox for the codelivery of anticancer drug paclitaxel (PTX) and small interference RNA (siRNA) targeting polo‐like kinase1 (PLK1) is developed to address the key challenges of multidrug‐resistant (MDR) cancer therapy. The ATP‐depleting micelle is self‐assembled from a redox‐responsive amphiphilic polymer (termed as bPEG‐SS‐P123‐PEI (PSPP)) that is composed of biocompatible branched polyethylene glycol (PEG) with 8 arms (bPEG), ATP‐depleting Pluronic P123 (P123), and cationic low molecular weight polyethylenimine (PEI) blocks. Upon critical micelle concentration, the PSPP unimer self‐assembles into a well‐ordered multilayered nanostructure and is able to load PTX and siRNA targeting PLK1. The cleavage of disulfide linkages at intracellular glutathione‐rich reduction milieu not only promotes PTX and siRNA release, but also activates the fast ATP‐depletion action that is critical in preventing intracellular PTX efflux by multidrug‐resistant cancer cells. The combination of ATP depletion and siRNA inhibition by PSPP micelles is found to provide dual modulations for resensitizing multidrug‐resistant cancer cells for PTX treatment. As a result, the codelivery of PTX and PLK1 siRNA exerts a stronger combinational effect against tumor growth in MDR tumor models in vivo. The development of fast ATP‐depleting nanomicelle represents an original delivery strategy for the distinctive dual modulation of cancer MDR with spatial and temporal control.
The Prognostic Significance of 11q Deletion Detected by Fluorescence In Situ Hybridization (FISH) in Untreated Chronic Lymphocytic Leukemia (CLL): The MDACC Experience.
Authors: Apostolia-Maria Tsimberidou, Constantine Tam, William G. Wierda, Susan O’Brien, Susan Lerner, Hagop M. Kantarjian, Michael J. Keating
Journal: Blood (2007)
Sorafenib and Nilotinib Are Candidates to Overcome Imatinib Resistance in Myeloproliferation with FIP1L1-PDGFRA.
Authors: Nikolas von Bubnoff, Sivahari P Gorantla, Richard A. Engh, Taiana de Oliveira, Silvia Thoene, Espen Åberg, Christian Peschel, Justus Duyster
Journal: Blood (2009)
C-Jun Regulates ER Stress Signaling to Promote Chemotherapy Resistance in Acute Myeloid Leukemia
Authors: Chun Zhou, Daniela Di Marcantonio, Esteban Martinez, Nehal Solanki-Patel, Suraj Peri, Claudia Scholl, Stefan Fröhling, David L. Wiest, Stephen Matthew Sykes
Journal: Blood (2015)
Prolonged Inhibition of BCR Signaling and Suppression of B Cell Lymphoma through Irreversible Inhibition of Bruton’s Tyrosine Kinase
Authors: Erica Evans, Michael Sheets, Hugues Bernard, Thia St. Martin, Mariana Nacht, Rich Tester, Chuck Jewell, Hormoz Mazdiyasni, Russell Petter, William Westlin, Juswinder Singh
Journal: Blood (2008)